Dec 19, 2019
MediSieve Founder Honoured as MIT Technology Review’s Innovator Under 35
Dr George Frodsham has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
LONDON – December 19, 2019 – Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
Innovators Under 35 is an annual list that recognises outstanding innovators who are younger than 35.
Dr Frodsham said, “It is a real honour to be selected as one of the Innovators Under 35 by such a prestigious institution as MIT. It is further validation of the fantastic work being carried out by the MediSieve team. I am excited to join the community of other innovators from 2019 and previous years and look forward to engaging further with them and MIT.”
This monumental achievement now means that Dr Frodsham joins the global community of innovators, pioneers and social changemakers curated by MIT Technology Review.
The awards span a wide range of fields, including biotechnology, materials, computer hardware, energy, transportation, communications, and the Internet. The panel consists of MIT Technology Review editors and experts in the tech ecosystem who evaluate and select the best projects for this year's edition.
Innovators Under 35 looks for individuals whose superb technical work promises to shape the coming decades. Their goal is to recognise the development of new technology or the creative application of existing technologies to solve the world’s biggest problems. They reward ingenious and elegant work that matters to the world at large—not just to peers in a particular field or industry.
MediSieve is the medical device company which is developing ‘magnetic blood filtration’. Their technology can potentially transform the treatment of blood-borne diseases including sepsis, leukaemia, and malaria in a process that’s similar to dialysis.
2019 has already been a year to remember for MediSieve. The company recently announced that they were a winner of the ‘Breakthrough Medical or Healthcare Device Award’ in the Beanstalks competition 2019. Earlier this year, Dr Frodsham won the Early Career Impact Award at the BBSRC Innovator of the Year Awards 2019. The company also won the highly competitive award category of Investment Achievement at the MedTech London Awards 2019, part of the annual Mayor of London Awards.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
